Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

In vitro and in vivo effects of 2,4 diaminoquinazoline inhibitors of the decapping scavenger enzyme DcpS: Context-specific modulation of SMN transcript levels.

Cherry JJ, DiDonato CJ, Androphy EJ, Calo A, Potter K, Custer SK, Du S, Foley TL, Gopalsamy A, Reedich EJ, Gordo SM, Gordon W, Hosea N, Jones LH, Krizay DK, LaRosa G, Li H, Mathur S, Menard CA, Patel P, Ramos-Zayas R, Rietz A, Rong H, Zhang B, Tones MA.

PLoS One. 2017 Sep 25;12(9):e0185079. doi: 10.1371/journal.pone.0185079. eCollection 2017.

2.

Intermittent oral coadministration of a gamma secretase inhibitor with dexamethasone mitigates intestinal goblet cell hyperplasia in rats.

Aguirre SA, Liu L, Hosea NA, Scott W, May JR, Burns-Naas LA, Randolph S, Denlinger RH, Han B.

Toxicol Pathol. 2014;42(2):422-34. doi: 10.1177/0192623313486315. Epub 2013 May 7.

PMID:
23651588
3.

N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: strategies to eliminate reactive metabolites.

Nair SK, Matthews JJ, Cripps SJ, Cheng H, Hoffman JE, Smith C, Kupchinsky S, Siu M, Taylor WD, Wang Y, Johnson TO, Dress KR, Edwards MP, Zhou S, Hosea NA, Lapaglia A, Kang P, Castro A, Ermolieff J, Fanjul A, Vogel JE, Rejto P, Dalvie D.

Bioorg Med Chem Lett. 2013 Apr 15;23(8):2344-8. doi: 10.1016/j.bmcl.2013.02.066. Epub 2013 Feb 24.

PMID:
23489629
4.

Predicting pharmacokinetic profiles using in silico derived parameters.

Hosea NA, Jones HM.

Mol Pharm. 2013 Apr 1;10(4):1207-15. doi: 10.1021/mp300482w. Epub 2013 Mar 7.

PMID:
23427934
5.

Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding.

Zhu Z, Shi M, Hu W, Estrella H, Engebretsen J, Nichols T, Briere D, Hosea N, Los G, Rejto PA, Fanjul A.

BMC Genomics. 2012 Jul 31;13:355. doi: 10.1186/1471-2164-13-355.

6.

Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.

Guo C, Kephart S, Ornelas M, Gonzalez J, Linton A, Pairish M, Nagata A, Greasley S, Elleraas J, Hosea N, Engebretsen J, Fanjul AN.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1230-6. doi: 10.1016/j.bmcl.2011.11.068. Epub 2011 Dec 9.

PMID:
22197140
7.

Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.

Guo C, Linton A, Kephart S, Ornelas M, Pairish M, Gonzalez J, Greasley S, Nagata A, Burke BJ, Edwards M, Hosea N, Kang P, Hu W, Engebretsen J, Briere D, Shi M, Gukasyan H, Richardson P, Dack K, Underwood T, Johnson P, Morell A, Felstead R, Kuruma H, Matsimoto H, Zoubeidi A, Gleave M, Los G, Fanjul AN.

J Med Chem. 2011 Nov 10;54(21):7693-704. doi: 10.1021/jm201059s. Epub 2011 Oct 7.

PMID:
21936524
8.

Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling.

Jones HM, Gardner IB, Collard WT, Stanley PJ, Oxley P, Hosea NA, Plowchalk D, Gernhardt S, Lin J, Dickins M, Rahavendran SR, Jones BC, Watson KJ, Pertinez H, Kumar V, Cole S.

Clin Pharmacokinet. 2011 May;50(5):331-47. doi: 10.2165/11539680-000000000-00000.

PMID:
21456633
10.

Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.

Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A, Tsaparikos K, Jani JP, Hosea N, Sands M, Randolph S, Smeal T.

Mol Cancer Ther. 2010 Jun;9(6):1618-28. doi: 10.1158/1535-7163.MCT-10-0034. Epub 2010 Jun 8.

11.

The development and SAR of pyrrolidine carboxamide 11beta-HSD1 inhibitors.

Cheng H, Hoffman J, Le P, Nair SK, Cripps S, Matthews J, Smith C, Yang M, Kupchinsky S, Dress K, Edwards M, Cole B, Walters E, Loh C, Ermolieff J, Fanjul A, Bhat GB, Herrera J, Pauly T, Hosea N, Paderes G, Rejto P.

Bioorg Med Chem Lett. 2010 May 1;20(9):2897-902. doi: 10.1016/j.bmcl.2010.03.032. Epub 2010 Mar 10.

PMID:
20363126
12.

Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease.

Helal CJ, Kang Z, Lucas JC, Gant T, Ahlijanian MK, Schachter JB, Richter KE, Cook JM, Menniti FS, Kelly K, Mente S, Pandit J, Hosea N.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5703-7. doi: 10.1016/j.bmcl.2009.08.019. Epub 2009 Aug 8.

PMID:
19700321
13.

N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275.

Siu M, Johnson TO, Wang Y, Nair SK, Taylor WD, Cripps SJ, Matthews JJ, Edwards MP, Pauly TA, Ermolieff J, Castro A, Hosea NA, LaPaglia A, Fanjul AN, Vogel JE.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3493-7. doi: 10.1016/j.bmcl.2009.05.011. Epub 2009 May 7.

PMID:
19473839
14.

Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.

Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K.

J Clin Pharmacol. 2009 May;49(5):513-33. doi: 10.1177/0091270009333209. Epub 2009 Mar 19.

PMID:
19299532
15.
16.

Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration.

Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J.

Drug Metab Dispos. 2006 Sep;34(9):1443-7. Epub 2006 Jun 7.

PMID:
16760229
17.

Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding.

Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J.

J Pharmacol Exp Ther. 2005 Jun;313(3):1254-62. Epub 2005 Mar 2.

PMID:
15743928
18.

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model.

Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CE, Kasman IN, Laperle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C.

Drug Metab Dispos. 2005 Jan;33(1):165-74. Epub 2004 Oct 22.

PMID:
15502009
19.

Purification of cytochromes P450: products of bacterial recombinant expression systems.

Guengerich FP, Hosea NA, Martin MV.

Methods Mol Biol. 1998;107:77-83. No abstract available.

PMID:
14577214
20.

Factors affecting the clinical development of cytochrome p450 3A substrates.

Gibbs MA, Hosea NA.

Clin Pharmacokinet. 2003;42(11):969-84. Review.

PMID:
12908853
21.

Purification of cytochrome P-450 enzymes.

Bell-Parikh LC, Hosea NA, Martin MV, Guengerich FP.

Curr Protoc Toxicol. 2002;Chapter 4:Unit4.2. doi: 10.1002/0471140856.tx0402s12.

PMID:
23045082
22.

Inactivation studies of acetylcholinesterase with phenylmethylsulfonyl fluoride.

Kraut D, Goff H, Pai RK, Hosea NA, Silman I, Sussman JL, Taylor P, Voet JG.

Mol Pharmacol. 2000 Jun;57(6):1243-8.

PMID:
10825396
23.

Elucidation of distinct ligand binding sites for cytochrome P450 3A4.

Hosea NA, Miller GP, Guengerich FP.

Biochemistry. 2000 May 23;39(20):5929-39.

PMID:
10821664
24.

Mechanism of oxime reactivation of acetylcholinesterase analyzed by chirality and mutagenesis.

Wong L, Radic Z, Brüggemann RJ, Hosea N, Berman HA, Taylor P.

Biochemistry. 2000 May 16;39(19):5750-7.

PMID:
10801325
25.

Analysis of cholinesterase inactivation and reactivation by systematic structural modification and enantiomeric selectivity.

Taylor P, Wong L, Radić Z, Tsigelny I, Brüggemann R, Hosea NA, Berman HA.

Chem Biol Interact. 1999 May 14;119-120:3-15. Review.

PMID:
10421434
26.

Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs.

Guengerich FP, Hosea NA, Parikh A, Bell-Parikh LC, Johnson WW, Gillam EM, Shimada T.

Drug Metab Dispos. 1998 Dec;26(12):1175-8. Review.

PMID:
9860923
27.

Oxidation of nonionic detergents by cytochrome P450 enzymes.

Hosea NA, Guengerich FP.

Arch Biochem Biophys. 1998 May 15;353(2):365-73.

PMID:
9606971
28.

Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5.

Shaw PM, Hosea NA, Thompson DV, Lenius JM, Guengerich FP.

Arch Biochem Biophys. 1997 Dec 1;348(1):107-15.

PMID:
9390180
29.
30.

Aspartate 74 as a primary determinant in acetylcholinesterase governing specificity to cationic organophosphonates.

Hosea NA, Radić Z, Tsigelny I, Berman HA, Quinn DM, Taylor P.

Biochemistry. 1996 Aug 20;35(33):10995-1004.

PMID:
8718893
31.

Structural bases for the specificity of cholinesterase catalysis and inhibition.

Taylor P, Radic Z, Hosea NA, Camp S, Marchot P, Berman HA.

Toxicol Lett. 1995 Dec;82-83:453-8. Review.

PMID:
8597093
32.

Specificity and orientation of trigonal carboxyl esters and tetrahedral alkylphosphonyl esters in cholinesterases.

Hosea NA, Berman HA, Taylor P.

Biochemistry. 1995 Sep 12;34(36):11528-36.

PMID:
7547883

Supplemental Content

Support Center